Approved for 6 indications
Treatment of DVT
Treatment of PE
Reduction in the risk
of recurrent DVT
and PE following
initial therapy
Reduction in risk
of stroke/systemic
embolism in NVAF
Prophylaxis of DVT, which
may lead to PE, after hip
replacement surgery
Prophylaxis of DVT, which
may lead to PE, after knee
replacement surgery
Learn more about ELIQUIS for the treatment of DVT/PE
and access reprints of our clinical studies.
hcp.eliquis.com
NVAF=nonvalvular atrial fibrillation; DVT=deep vein thrombosis; PE=pulmonary embolism.
SELECTED IMPORTANT SAFETY INFORMATION (CONT’D)
DRUG INTERACTIONS (CONT’D)
• Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases
the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with
aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.
PREGNANCY CATEGORY B
• There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage
during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the
mother and fetus.
Please see Brief Summary of Full Prescribing Information, including Boxed WARNINGS, on the adjacent pages.